Upon histopathological inspection in two independent cohorts (Oslo2 Landscape, n = 40, and Oslo1, n = 530), co-elevation of EGFR and MET appears to be confined to ductal carcinoma in situ (DCIS) regions for a subset of normal-like tumors (Fig. 4e–g, Supplementary Fig. 9, Supplementary Data 3), and high-resolution images of these regions in two tumors suggest EGFR-MET co-localization may confer an advantage for their in situ survival (Fig. 4h). This evidence concerns the gene MET and ductal breast carcinoma in situ.